The effect of trametinib on lung cancer

Trametinib(trametinib) isan oral MEK inhibitor selective for MEK1 and MEK2. Trametinib is used in combination with dabrafenib for the treatment of BRAF Metastatic non-small cell lung cancer (NSCLC) in patients with V600E mutations (designated as an orphan drug by the FDA when used in combination).

Dabrafenib plus trametinib was found to have potent antitumor activity in patients withBRAF V600E mutant metastatic NSCLC (mNSCLC). Updated survival analysis of a phase 2 study (NCT01336634) with at least 5 years of follow-up and updated genomic data.

Methods: Pretreated (cohort B) and treatment-naïve (cohort C) patients with BRAF V600E mutant mNSCLC received dabrafenib 150 mg twice daily and trametinib 2 mg once daily. The primary endpoint was investigator-assessed overall response rate according to Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints were duration of response, progression-free survival, overall survival and safety.

Results: At data cutoff, the median follow-up was 16.6 (range: 0.5-78.5) and 16.3 (range: 0.4-80) months, and the overall response rate (95% confidence interval [CI]) was 68.4% (54.8-80.1) and 63.9% for Cohort B (57 patients) and Cohort C (36 patients) (46.2-79.2), with a median progression-free survival (95% CI) of 10.2 (6.9-6.9). The 4- and 5-year survival rates were 26% and 19%, respectively, in pretreated patients and 34% and 22%, respectively, in untreated patients. A total of 17 patients (18%) are still alive. The most common adverse event was pyrexia (56%). Exploratory genomic analyzes suggest that coexisting genomic alterations may influence clinical outcomes in these patients; however, these results require further investigation.

Conclusion: In patients with BRAF V600E mutant mNSCLC, treatment with dabrafenib combined with trametinib was found to have significant and durable clinical benefit, regardless of prior treatment, with a manageable safety profile. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.